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INTRODUCTION
The phenomenon of local IPC (ischaemic preconditioning) induced by short periods of ischaemia and reperfusion is well recognized as one of the most potent innate protective mechanisms against IR (ischaemia/reperfusion) injury [1] . However, despite the wealth of experimental evidence showing that IPC significantly reduces infarct size and post-ischaemic dysfunction, its translation into clinical practice has been limited because of the difficulty in rendering the target organ (e.g. the heart) ischaemic prior to a predictable insult. rIPC (remote IPC) is a more recently described method whereby transient ischaemia and reperfusion of one tissue or organ confers protection against a subsequent prolonged period of ischaemia in a distant organ. First described in separate vascular territories within the heart [2] , subsequent studies in rodents have shown that cardioprotection could be induced by using transient renal artery occlusion [3] , mesenteric ischaemia [4] and with electrical stimulation of a partially ischaemic limb [5] . Although effective at reducing myocardial infarction size, these methods were similarly limited by their lack of clinical applicability.
In 2002, we described a simpler method of inducing rIPC by brief periods of limb ischaemia using a blood pressure cuff or tourniquet. This form of rIPC has comparable effects with those of local IPC in experimental models, reducing the extent of myocardial infarction in a porcine model by 50 % [6] . Because of its facile nature, it has been rapidly translated into randomized clinical trials. In children, rIPC protects against myocardial injury, improves lung dysfunction and modifies the inflammatory response after open heart operations [7] . In adults, rIPC has been shown to decrease markers of myocardial injury after coronary bypass surgery, reduce post-operative myocardial infarction and renal failure after abdominal aneurysm surgery, and reduce troponin release and angina-pain during elective and emergency coronary angioplasty [8, 9] . However, although rIPC has a potentially important clinical role, our understanding of the mechanistic pathways linking the local stimulus to the remote organ remains incomplete. We have recently shown [10] that transient limb ischaemia in rabbits releases a circulating factor, the physical properties of which have been partially characterized, and increases myocardial expression of p42/p44 MAPK (mitogen-activated protein kinase) and induces subcellular redistribution of PKCε (protein kinase Cε).
The PI3K (phosphoinositide 3-kinase)/Akt pathway has been shown to play a critical role in regulating cell growth and cell survival in different systems. Previous studies have demonstrated that PI3K-mediated prosurvival pathway is involved in cardioprotection induced by local IPC [11, 12] . Tong et al. [13] have also shown that phosphorylation and subsequent inactivation of GSK3β (glycogen synthase kinase 3β) via the PI3K/ Akt pathway is an important element in the cardioprotective effects of local IPC. Moreover, Ban et al. [14] used PI3Kγ -knockout mice to demonstrate the importance of the PI3Kγ /Akt/GSK3β signalling pathway in IPC. However, whether rIPC also activates the PI3K/ Akt/GSK3β pathway as in local IPC remains to be determined.
GSK3β is not only a downstream target of the PI3K/Akt pathway, but it is also involved in the Wnt pathway. Activation of the PI3K/Akt pathway results in the phosphorylation of GSK3β at position Ser 9 and subsequent inactivation of GSK3β, leading to β-catenin accumulation and translocation from the cytosol to the nucleus [15] . β-Catenin is one of the important molecules in the Wnt pathway, mediating anti-apoptotic effects by regulating the expression of several important antiapoptotic genes in cardiomyocytes through interaction with the TCF/LEF (T-cell factor/lymphoid enhancer factor) family of transcription factors [16] . Furthermore, the downstream targets of β-catenin, E-cadherin, a key protein in cell-cell adhesion [17] , and the PPAR (peroxisome-proliferator-activated receptor) subfamily (γ , α and δ), which are master transcriptional regulators for a host of genes that regulate tissue-specific nutrient metabolism and energy homoeostasis [18] , may be important in cell-survival regulation. In particular, PPARδ is the predominant subtype in the heart [19] where it plays an important role in cardiac metabolism by regulating the expression of genes involved in fatty acid and glucose utilization [20] , and its expression is regulated by nuclear β-catenin [21] . Interestingly, in a recent study [22] , PPARδ induced the up-regulation of extracellular matrix proteins exerting an anti-apoptotic effect, although its role in preconditioning has not been studied previously.
Although local IPC and rIPC share similar end-organ effects, it cannot be assumed that rIPC simply recapitulates the cellular mechanisms of local IPC. Indeed, there are important differences in the upstream signalling pathways when the two stimuli are compared [23] , and significant differences even exist depending on the mode of stimulus of rIPC [24] . We therefore examined the hypothesis that the myocardial protection afforded by rIPC is mediated via the PI3K/Akt/GSK3β signalling pathway, activation of which is associated with nuclear accumulation of β-catenin and up-regulation of its target genes E-cadherin and PPARδ in a mouse I/R model. 
MATERIALS AND METHODS

Ethics
Induction of rIPC
C57/BL6 male mice (8-10 weeks of age) were used in the present study. Mice were anaesthetized with pentobarbital [60 mg/kg of body weight, i.p. (intraperitoneally)]. rIPC was induced by four cycles of 5 min of femoral artery occlusion (by tourniquet), followed by 5 min of reperfusion as described previously [25, 26] . Unilateral limb ischaemia was achieved non-invasively by applying direct pressure to the femoral vessels using a tourniquet tightened at the inguinal level. Distal limb pallor was observed during occlusion, followed rapidly by brisk reactive hyperaemia during reperfusion. At 15 min after the end of the rIPC protocol, the heart was isolated for study.
Isovolumic Langendorff preparation and global ischaemia model
Mice received heparin (200 units, i.p.; Sigma), were anaesthetized with pentobarbital (60 mg/kg of body weight, i.p.; Ceva Sante animale), and then intubated and ventilated. Hearts were rapidly excised by bilateral thoracotomy, placed in ice-cold buffer and the aorta was cannulated with a 20-gauge metal cannula. Isolated hearts were mounted on the Langendorff perfusion apparatus (Radnoti Technologies) and perfused under non-recirculating conditions at a constant pressure of 80 mmHg with 37
• C KHB (Krebs-Henseleit buffer) (120.0 mmol/l NaCl, 25.0 mmol/l NaHCO 3 , 4.7 mmol/l KCl, 1.2 mmol/l MgSO 4 , 1.2 mmol/l KH 2 PO 4 , 2.5 mmol/l CaCl 2 , 0.5 mmol/l EDTA and 15 mmol/l glucose). The solution was continuously gassed with 95 % O 2 /5% CO 2 (pH 7.4). Once placed on to the perfusion apparatus, hearts were submerged in 37
• C KHB during the experiment. The left auricule was removed and a balloon, made with saran wrap and PE60 polyethylene tubing, was inserted into the left ventricle through the mitral valve and was connected to a pressure transducer (ML844; AD Instruments). The balloon was inflated with water to adjust the LVEDP [LV (left ventricular) end-diastolic pressure] to 7-10 mmHg at the beginning of the experiment and the volume was kept constant for the duration of the study. After a 20 min stabilization period, hearts were subjected to 30 min of no-flow global ischaemia, followed by 60 min of reperfusion. The haemodynamic measurements, including HR (heart rate), peak LVP (LV pressure), +dP/dt max (maximum rate of contraction), − dP/dt min (maximum rate of relaxation) and LVEDP were recorded with a PowerLab data acquisition system (ADInstruments). The LVDP (LV developed pressure) was calculated as the difference between the systolic and end-diastolic LV pressures. CFR (coronary flow rate) was calculated by measuring the amount of effluent emerging from the heart during a 1 min collection (ml/min)
Experimental protocols
Protocol 1: Akt/GSK3β/β-catenin signalling following rIPC in normal mice C57/BL6 mice were divided into four groups. Control or rIPC (four cycles of 5 min of hindlimb ischaemia and 5 min of reperfusion) and/or inhibitor administration was performed prior to heart harvest ( Figure 1 ). The sham procedure in the control group comprised no treatment for 65 min under anaesthesia; mouse hearts in these groups were harvested at 15 min after rIPC or at the end of the sham period. WM (wortmannin), a PI3K inhibitor, was delivered intravenously. However, there was no Langendorff preparation, instead hearts were isolated and analysed directly for Western blot and immunostaining.
Protocol 2: the induction of cardioprotection by rIPC I/R injury (30 min of global ischaemia/60 min of reperfusion) was induced in isolated mouse hearts mounted on an isovolumic Langendorff system. Sham procedure or rIPC and/or inhibitor administration was performed prior to heart harvest as in protocol 1. Mice were divided into four groups and the experimental protocol, timeline and dosage of inhibitors for each group are shown in Figure 1 . At the end of the isovolumic Langendorff study, each heart was harvested for TTC (triphenyltetrazolium chloride) staining to evaluate infarction size, or for Western blot analysis and real-time PCR.
Measurement of infarct size
At the end of reperfusion period, hearts were weighed and frozen at − 80
• C. The frozen heart was cut transversely into 1-mm-thick slices using a Mouse Heart Slicer Matrix (Zivic Instruments), and stained with 1.25 % TTC in 200 mM Tris/HCl (pH 7.4) for 15 min in a 37
• C water bath. After fixation for 4-6 h in 10 % neutral buffered formaldehyde, both sides of each slice were photographed by electronic scanning (CanoScan 4400F). The viable myocardium stained brick red, and infarct tissues appeared pale white. Infarct and LV area were measured using automated planimetry using Adobe Photoshop ® CS2 software, with the infarct size expressed as a percentage of the total LV area. 
TUNEL (terminal deoxynucleotidyltransferase-mediated dUTP nick-end labelling) assay
Cryostat sections were prepared to perform TUNEL assays using the ApopTag Plus Peroxidase In situ Apoptosis Detection Kit (Chemicon), according to the manufacturer's instructions. The percentage of nuclei labelled by TUNEL per unit of cells stained with nuclear dye reflected the apoptotic index.
Immunoblotting
After harvest, each heart was snap frozen in liquid nitrogen and stored at − 80
• C for future analysis. Cytosolic and nuclear proteins were separated as described previously [27] . In brief, frozen hearts were ground with a mortar and pestle in liquid nitrogen and then homogenized in lysis buffer [0.6 % Nonidet P40, 150 mM NaCl, 10 mM Hepes (pH 7.9), 1 mM EDTA, 2.5 mM Na 4 O 7 P 2 , 1 mM 2-glycerolphosphate, 1 mM Na 3 VO 4 and a cocktail of protease inhibitors (Roche)]. The homogenate was centrifuged at 10 000 g at 4
• C for 5 min to obtain the cytosolic fraction (supernatant). Then the pellet was solubilized in nuclear lysis buffer [25 % glycerol, 20 mM Hepes (pH 7.9), 420 mM NaCl, 1.2 mM MgCl 2 , 0.2 mM EDTA, 0.5 mM dithiothreitol and a cocktail of proteases inhibitors] and centrifuged at 12 000 g for 10 min to obtain the nuclear fraction (supernatant). An equal amount of protein (30 μg of cytosolic protein or 10 μg of nuclear protein) from each sample was separated by SDS/PAGE (10 % gels) and transferred on to nitrocellulose membranes (Bio-Rad Laboratories). Membranes were incubated with rabbit monoclonal antibodies against phosphoAkt (Ser 473 ), Akt, phospho-GSK3β (Ser 9 ) and GSK3β (Cell Signaling Technology) and β-catenin (Sigma) overnight at 4
• C. The membranes were then washed and subsequently incubated with an HRP (horseradish peroxidase)-conjugated secondary antibody (Santa Cruz Biotechnology), and antibody binding was detected with the ECL (enhanced chemiluminescence) plus Detection Kit (Amersham). Immunoblots were scanned using a Storm 840 analyser (Molecular Dynamics) and quantified using ImageQuant 5.0 software (Molecular Dynamics).
Immunostaining
Cryostat sections (5-μm-thick) were prepared, air-dried and fixed in 4 % paraformaldehyde/PBS for 10 min. The sections were incubated with 0.3 % H 2 O 2 for 10 min and 10 % BSA for 30 min. The sections were then incubated with an antibody against β-catenin (Sigma) at 4
• C overnight. Bound antibody was detected with the Vectastain ABC kit (Vector Laboratories), visualized with DAB (diaminobenzidine; Sigma) and counterstained with haematoxylin. Negative controls were performed for all immunological staining by omission of the primary antibody.
Real-time PCR
Total RNA was extracted from LV tissue using TRIzol ® Reagent (Invitrogen). Reverse transcription proceeded with 1 μg of total RNA using the SuperScript ® III FirstStrand Synthesis System (Invitrogen). Real-time PCR was carried out with SYBR Green Master Mix (Applied Biosystems). GAPDH (glyceraldehyde-3-phosphate dehydrogenase) was used as the endogenous reference. Primers are listed as follows: E-cadherin, forward 5 -TGTGGATGACTGAGTACCTGAAC-3 and reverse 5 -AGGAGAAATCAAACAGAGGTCG-3 ; PPARδ, forward 5 -AGAGGCTCCTGCTCACTGACA-3 and reverse 5 -GTCATAGCTCTGCCACCATCTG-3 ; and GAPDH, forward 5 -GACGGCCGCATCTTCTTG-3 and reverse 5 -TTCACACCGACCTTCACCATT-3 .
Statistical analysis
Statistical significance was determined using one-way ANOVA, followed by a post-hoc testing (NewmanKeuls test). Values of P 0.05 were considered statistically significant. Values are shown as means + − S.E.M.
RESULTS rIPC activates the PI3K/Akt/GSK3β signalling pathway in normal mouse heart
These studies examined the effect of rIPC on components of the RISK (reperfusion injury salvage kinase) signalling pathway, including PI3K and GSK3β, to understand the cardioprotective phenotype induced by the rIPC in the normal heart. As shown in Figure 2 , rIPC significantly (P < 0.01) increased protein levels of phospho-Akt (1.7 + − 0.1-fold compared with control) (Figures 2A and  2B ) and phospho-GSK3β (1.6 + − 0.1-fold compared with control) (Figures 2A and 2C) . Consistent with its inhibitory activity, pre-treatment with WM significantly reduced the levels of phospho-Akt (0.3 + − 0.1-fold in WM+rIPC compared with control), a known target of PI3K. Furthermore, the relative levels of phospho-GSK3β, a downstream target of Akt, were also significantly reduced (0.5 + − 0.1-fold compared with control) (Figures 2B and 2C) .
rIPC affects the β-catenin signalling pathway in normal mouse heart As GSK3β activity has been shown to constitutively phosphorylate β-catenin, a component of the TCF/LEF transcription factor, we examined the effects of rIPC alone and in combination with WM on cytosolic and nuclear levels of β-catenin (Figure 3) . Compared with control animals, rIPC significantly (P < 0.05) increased cytosolic and nuclear β-catenin levels in hearts (1.3 + − 0.1-and 1.7 + − 0.2-fold in cytosolic and nuclear levels respectively compared with control) (Figures 3A  and 3B ). Pre-treatment with WM prior to rIPC reduced cytosolic and nuclear levels of β-catenin 1.6-fold and 2.5-fold respectively compared with β-catenin accumulation in rIPC-treated animals. To corroborate these findings using an orthogonal approach, we have used heart sections immunostained with an antibody specific for β-catenin to demonstrate increased levels of β-catenin in the nuclei from rIPC tissues relative to control tissues ( Figure 3C ). Together, these findings suggest that rIPC results in inhibited β-catenin phosphorylation and degradation, and increased accumulation of β-catenin in the cytoplasm, and its translocation to the nucleus is, at least in part, through the activation of PI3K/Akt/GSK3β.
rIPC up-regulates E-cadherin and PPARδ mRNA levels
To determine whether genes shown previously to be up-regulated by β-catenin are associated with rIPC, we performed real-time PCR for E-cadherin and PPARδ mRNAs in perfused heart tissues after I/R injury. rIPC significantly (P 0.05) increased levels of Ecadherin mRNA (2.7-fold) and PPARδ mRNA (2.0-fold) compared with sham animals.
Figure 3 rIPC increases β-catenin levels in normal mouse hearts
(A) Western blots of cytosolic (Cyto) and nuclear fractions prepared from hearts in each treatment group was probed sequentially with primary antibodies against β-catenin and GAPDH (cytosolic fraction) or transcription factor IIB (TFIIB; nuclear fraction). Ctrl, control. (B) and (C) Protein levels of cytosolic (B) or nuclear (C) β-catenin. For quantification, cytosolic or nuclear levels of β-catenin were normalized to GAPDH or TFIIB respectively. *P < 0.05 compared with control, WM or WM+rIPC. Results are means + − S.E.M., n = 6 for all groups. (D) Increased levels of β-catenin in cardiomyocyte nuclei in rIPC hearts. Representative images of heart tissue sections from control (a) and rIPC (b) groups counterstained with haemotoxylin, following immunostaining for β-catenin, are shown. Arrows indicate immunostained nuclei.
Effects of rIPC and pharmacological interventions on ventricular function following global ischaemia (haemodynamics)
The effects of the in vivo interventions on three functional parameters, including haemodynamic performance, infarct size and apoptosis, were monitored using isolated perfused hearts from the various groups. There were no statistically significant differences in baseline haemodynamic functional parameters among all of the groups ( Table 1) . As shown in Figure 4 , prior in vivo rIPC improved post-ischaemic cardiac performance in isolated perfused hearts. A representative LVDP recording from sham and rIPC hearts is shown in Figure 4(A) . On the basis of the LVDP, recovery of post-ischaemic contractile function was greater in rIPC hearts than in sham hearts ( Figure 4B ). Pre-ischaemic LVDP was 90 mmHg in both sham and rIPC hearts and fell to 0 mmHg during the 30 min period of ischaemia. Within 5 min of the beginning of reperfusion, LVDP increased to 40.2 mmHg in the rIPC hearts, but to only 13.8 mmHg in the sham hearts. By the end of the 60 min reperfusion period, a significantly (P < 0.05) greater functional recovery was observed in rIPC hearts (80.9 + − 5.0 % of preischaemic value) compared with sham (55.2 + − 5.6 % of pre-ischaemic value) ( Figure 4B ). Maximal rates of contraction (dP/dt max ) and maximal rates of relaxation (dP/dt min ) were also significantly (P < 0.05) increased (improved) in rIPC hearts compared with sham hearts (dP/dt max , 83.3 + − 4.6 and 52.3 + − 5.2 % in rIPC compared with sham hearts; dP/dt min , 77.0 + − 4.7 and 52.1 + − 6.0 in rIPC compared with sham hearts) ( Figures 4C  and 4D ). These results indicated that post-ischaemic contractile function was improved by rIPC. Diastolic recovery was also improved by rIPC; there were major differences between rIPC and sham hearts in postischaemic recovery of cardiac function as judged by the attenuation of the elevation in LVEDP that occurred during the 60 min reperfusion period ( Figure 4E ). In rIPC hearts, LVEDP was significantly lower than that of sham hearts at the beginning of reperfusion and decreased steadily throughout the reperfusion period. In contrast, sham hearts had an initial increase in LVEDP at 5 min of reperfusion, which was followed by a gradual decrease. At the end of the reperfusion period, LVEDP was significantly (P < 0.05) lower in rIPC hearts (22.1 + − 3.3 mmHg) than in sham hearts (42.9 + − 5.8 mmHg) ( Figure 4E ). In the group treated with WM prior to rIPC (WM+rIPC), no significant differences in LVDP, dP/dt min , dP/dt max or LVEDP were observed relative to the sham groups.
Effects of rIPC and pharmacological interventions on infarct size following global ischaemia
Following global ischaemia and reperfusion, myocardial infarct size was assessed by TTC staining ( Figure 5 ). Consistent with the improved functional recovery, infarct size was significantly (P < 0.05) reduced by rIPC (19 + − 4 %) compared with sham (39 + − 7 %), and this effect was reversed by pre-treatment with WM [39 + − 5 %; P = ns (not significant) compared with sham]. WM pretreatment alone did not result in a significant difference in infarct size compared with sham hearts.
Effects of rIPC and pharmacological interventions on apoptosis following global ischaemia
We also performed TUNEL assays on the hearts in each of the groups to study the potential anti-apoptotic effects of the treatment regimens ( Figure 6 ). Apoptotic cells were rarely seen in the hearts of control mice (0.17 %), and rIPC significantly (P < 0.01) decreased the number of TUNEL-positive cells ( Figure 6A ) compared with sham group (0.16 + − 0.02 % compared with 0.32 + − 0.03 % respectively) ( Figure 6B ). Interestingly, WM alone increased the percentage of apoptotic cells (1.1 %), and this was unaffected by subsequent rIPC (0.8 %; P = ns).
DISCUSSION
The present study provides several novel findings that increase our understanding of the signal transduction mechanism of the cardioprotection afforded by rIPC in vivo. First, P13K activity is necessary for the increase in phosphorylation of Akt and GSK3β associated with rIPC. Secondly, rIPC also resulted in increased accumulation of β-catenin in the cytoplasm and translocation from the cytosol to nucleus, which were dependent on PI3K/Akt/GSK3β activity. Thirdly, we found that PI3K activity is required for the induction of cardioprotection by rIPC. Lastly, on the basis of these observations, we show for the first time that rIPC increases mRNA levels of E-cadherin and PPARδ, genes that are under the transcription control of β-catenin and also have been shown to be involved in cell-survival signalling. Emerging evidence from animal studies suggests that some of the underlying mechanistic pathways and signal transduction cascades activated by rIPC may be similar to those recruited in the setting of local IPC [28] , including adenosine receptor stimulation [3] , activation of K ATP channels [3, 25] , protection of mitochondrial structure and function [29] , and activation of intracellular kinases such as PKC [4] . Our recent study [10] showed that rIPC induced by transient limb ischaemia induces the translocation of PKCε from the cytosol to membranes in the myocardium subjected to rIPC in vivo. Furthermore, we showed increases in MAPKs, also key elements in the cell-signalling pathway of local IPC, confirming the findings of Heidbreder et al. [30] , who have demonstrated a similar involvement of MAPKs in rIPC induced by mesenteric artery ischaemia. We have also shown that rIPC and local postconditioning work in an additive way to increase phospho-Akt and phospho-ERK1/2 (extracellular-signal-regulated kinase 1/2) levels [31] in hearts subjected to regional I/R injury in vivo. We also found that rIPC increased phospho-ERK1/2 levels in mouse heart (results not shown). However, there are no data systematically examining the role of the PI3K/Akt pathway in rIPC, and there are only limited data regarding the role of β-catenin in the cardioprotection afforded by local IPC [32] .
It is well known that activation of PI3K is important in the intracellular signalling leading to cardioprotection by local IPC. Downstream targets of PI3K in local IPC include the phosphorylation of components of the PI3K/Akt pathway and the phosphorylation of GSK3β [13] , and this forms an important element of the RISK pathway proposed by Yellon's group [12] . In the present study, we report that rIPC increases the phosphorylation of Akt in the normal heart, resulting in increased phosphorylation and thereby inactivation of GSK3β, both of which were blocked by pre-treatment with the PI3K inhibitor WM. This supports the notion that rIPC activates the PI3K/Akt signalling pathway and increases phosphorylation of GSK3β through a PI3K/Akt-dependent pathway. Furthermore, in the I/R model, rIPC effectively induces cardioprotection against a subsequent ischaemic insult; however, rIPC-induced cardioprotection was also blocked by WM, and as such, rIPC acts mechanistically via similar pathways to those of local IPC.
Multiple pathways other than the PI3K/Aktdependent pathway may regulate the activity of GSK3β, such as the Wnt signalling pathway. GSK3β has been implicated in a variety of physiological processes such as induction of apoptosis [33] . GSK3β also controls cell survival through regulation of β-catenin, one of the important molecules in Wnt signalling [34] . β-Catenin is phosphorylated in a cytosolic multiprotein complex containing APC (adenomatous polyposis coli protein), Axin and GSK3β [35, 36] . When phosphorylation of β-catenin is blocked by phosphorylation of GSK3β, cytosolic β-catenin degradation is attenuated, resulting in increased accumulation in the cytosol and translocation from the cytosol into the nucleus [15] . As we (present study) and others [32, 37] have observed, concomitant with increased phosphorylation of GSK3β, increased levels of β-catenin are also observed in the cytosol and nucleus. Once in the nucleus, β-catenin acts as a transcriptional coactivator and activates genes involved in cell proliferation and survival [38] . Studies have demonstrated the role of β-catenin in regulating survival/apoptosis and hypertrophy of cardiomyocytes in response to statin-induced resistance to reoxygenation injury [16] , and have shown that β-catenin overexpression reduced myocardial infarct size, had an anti-apoptotic effect and modified cell-cycle activation in cardiomyocytes and cardiac fibroblasts [39] .
In the only previous study into the role of β-catenin in preconditioning [32] , it was reported that local IPC led to the accumulation of β-catenin in the cytosol and nucleus after inhibition of GSK3β, and may therefore play an important role in the angiogenesis and cardioprotection induced by local IPC. The present study is the first to demonstrate that rIPC induces the phosphorylation of GSK, resulting in an increase in cytosolic β-catenin accumulation, leading to its translocation to the nucleus. Blockade of β-catenin was associated with reduced nuclear β-catenin, albeit with a smaller than expected increase in cytosolic levels, and reversed the protective effects of rIPC on both functional recovery and infarct size after I/R injury.
Furthermore, our present study has demonstrated that rIPC increased the mRNA expression of the β-catenintarget genes E-cadherin and PPARδ, both of which may be crucial to cell survival after ischaemic stress. Given the short time frame of the experiments, the elevated levels of E-cadherin and PPARδ are more indicative of the panel of genes that are associated with the cardioprotected state induced by rIPC. It is perhaps more likely that the functional effects of elevated levels of PPARδ mRNA will be evident in the longer-term effects associated with rIPC. Additionally, given that AMPK (AMP-activated protein kinase) has been shown to be activated following IPC of the liver [40] , we cannot rule out the possibility that AMPK acting together with the transcriptional factor PGC1α (PPARγ coactivator 1α) could be responsible for the elevated levels of PPARδ mRNA [41] .
Although it was beyond the scope of the current studies to measure the functional effects of this observation, for example protein levels and further effects on downstream targets, previous studies have suggested that cell-cell interactions control cell survival, particularly via the classical cadherins, a family of transmembrane proteins promoting calcium-dependent cell-cell adhesion. Cadherin homophilic ligation initiates the assembly of large adhesion multimolecular complexes, which are connected to the actin cytoskeleton via proteins of the catenin family [42] . This connection is essential for the stabilization and the strength of cellcell junctions [43] . Cadherin engagement also leads to the transduction of intracellular signals [44] and has been shown to protect cells from anoikis [45] . The PPAR subfamily (γ , α and δ) are master transcriptional regulators for a host of genes that regulate tissuespecific nutrient metabolism, energy homoeostasis and inflammation [18] . PPARδ is the predominant subtype in the heart [19] and when overexpressed in mice results in decreased myocardial injury following ischaemia and reperfusion [46] . The role of PPARδ in protection against ischaemia and reperfusion has also been demonstrated in other organs, including brain, kidney and testes [47] . Given that IPC can improve athletic performance at maximal levels [48] , it is interesting that extended periods of pharmacological activation of PPARδ has been associated with improved performance of mice on a treadmill [41] and anatomical changes in the heart that resemble those found in animals undergoing longterm exercise [49] . Although the current time frame over which apoptosis was observed to be reduced may be too short to attribute to the anti-apoptotic effects of PPARδ in heart endothelial cells described previously [47] , the elevated levels of mRNA may have relevance to the reduced levels of apoptosis observed in the second window (24 h) of protection after IPC [50] . The findings described above both highlight the long-term physiological effects of PPARδ expression/activation and point to the potential importance of elevated levels of PPARδ mRNA in the later window of protection induced by rIPC, and represent areas for future investigation.
In summary, the myocardial protection afforded by rIPC induced by transient limb ischaemia is mediated via the PI3K/Akt/GSK3β signalling pathway, activation of which is associated with cytosolic and nuclear accumulation of β-catenin and the expression of the β-catenin target genes E-cadherin and PPARδ, which are involved in cell-survival signalling. On the basis of these latest results, in combination with our previous findings, we can formulate a model whereby the rIPC stimulus of transient limb ischaemia results in the release of factor(s) into the bloodstream [10] that circulate to tissues and bind to receptors on the cell surface to activate the cascades of PI3K/Akt/GSK3β and ERK1/2 pro-survival kinase signalling characterized by immediate post-translational and subsequent transcriptional events similar to that of local IPC.
